Innovative, Quantitative, Data Driven

Dr. Lukasz Konopka’s Brain to Behavior neurodiagnostic & neuromodulation program (B to B) utilizes innovative methods including quantitative assessments to diagnose patients.

Dr. Konopka develops an informed treatment plan based on these objective, data driven findings, which are the patient’s unique neurophysiological profile.

Integrative Clinical Approach with Meaningful Interpretation and Active Patient Collaboration,

Leads to Establishing New Habits & A Better Quality of Life

The Brain to Behavior model is an integrative clinical approach utilizing assessment tools such as:

  • genetic mapping
  • qEEG
  • physiological data from evoked potentials
  • emotional activation studies
  • cognitive neurobehavioral testing

and other data driven assessments to objectively evaluate brain to behavior correlates.

A comprehensive image of the relationship between symptoms and brain structure emerges by converging this array of objective data and is used as a clinical map for tailored treatment direction.

Dr. Konopka and his team can meaningfully interpret this map, tapping into the innate neuroplasticity of the brain. The patient is a partner and collaborates through active participation in the treatment plan to gradually restructure neural pathways, in order to modify behaviors through the establishment of new adaptive habits – and a better quality of life.

Meet Dr. Konopka, Program Director and Our Brain to Behavior Team

From left to right:

Restructuring Neural Networks & Addressing Each Aspect of the Patient’s Wholeness

To restructure the neural networks, a diverse set of qualified practitioners are employed to utilize a variety of treatment techniques within the Brain to Behavior team. Treatment is multi-disciplinary in nature and is enhanced through the synergy of evidence-based practices.

Neuromodulation techniques include bio-neurofeedback, advanced neuropsychological testing and other neuro-modulating tools such as Transcranial Magnetic Stimulation and Alpha Stim. Treatment is further enhanced by integrating Art Therapy and other creative expressive modalities such mindfulness practices, somatic awareness and visualization in order to improve quality of life.

Collectively, the Brain to Behavior team aims to address each aspect of the patient’s wholeness which is fulfilled not only physiologically or biologically but also psychologically, socially, and spiritually.

As cognitive and emotional flexibility increases, symptom management and brain remodeling is evident as patients are empowered to face life’s challenges and optimize their unique potential.

Ultimately, the collaboration between the Brain to Behavior team and the patient is determined largely by patient investment and dedication to personal development.

What is a qEEG

A qEEG is a subjective, diagnostic tool used to show your brain’s electrical activity.

A qEEGs is a painless, diagnostic test that records the electrical activity of your brain. It has no side-effects and is useful for determining brain related conditions such as attention disorders, anxiety, depression, stroke, tumor, head injury, memory difficulties and seizures.

Reasons you are asked to have a qEEG could be you have tried and failed medications and want a more definitive answer, unsure of your current diagnosis, you are having trouble remembering, you want a subjective test before starting medication, you would like to test the efficacy of your current medication.

A qEEG is a non-invasive procedure that takes about 3 hours. Your head is measured, and individual sensors, called  electrodes are placed upon your head based on the specific measurements found. An electrode will also be placed on each ear lobe, and one electrode to your chest for recording your heartbeat. We do not use caps, but individual electrodes at IPD.

You are asked to go through a set of tasks. Eyes closed, eyes open, 3 computerized tests, deep breathing and sleep.

We will also record while you use a laptop to interact with some computer-generated sounds and shapes.

Next, you will be asked to do some deep breathing for about three minutes, and lastly, you will rest in the recliner with your eyes closed for about twenty minutes. During that time, we would like you to be comfortable and relaxed, and if possible, take a brief nap. When the testing is complete, the technologist will remove the electrodes and try to remove most of the paste.

At home, any remaining paste can be removed by shampooing with warm water. It will take about ten days to analyze your data and write a report, so please schedule your follow-up appointment to discuss your results after that time. This information will aid in development of appropriate interventions that are tailored to your needs. If you have any other questions, please feel free to call the office or ask your technologist before the test.

By doing these tasks Dr Konopka can see how your brain functions. A qEEG can indicate things such as ADHD, depression, dementia, anxiety, seizure activity and past brain injuries.

How to schedule a qEEG

Call us at (815)942-6323

How to prepare for a qEEG

  • Get a good night’s rest
  • Eat breakfast or lunch (about 30 min to an hour before appt)
  • Take meds as usual (unless medication challenge)
  • No jewelry in ears
  • Comfortable clothing
  • Medication Challenge (if applicable) do not take medication before appt, will take at appt
  • Clean hair with no products-conditioner, gel, mousse, hairspray, etc.

What will happen after I get my qEEG?

  • An appointment will be made for 2 weeks out with Dr Konopka
  • Dr Konopka will present you with a PowerPoint of detailed information about the data collected during the qEEG

Call and schedule your test today and learn more about yourself.

Click here for qEEG Preparation Instructions.

Dr. Konopka's Publications

    Contact Alice Glowacki if you would like to obtain a copy of any publication

    • Exercise vs competitive athletics in youth: a neuroscience perspective. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(6), 581–582.
    • The “Brain to Behavior Approach” to diagnosis and treatment. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(5), 500–502.
    • Near death experience: neuroscience perspective. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(4), 392–393.
    • The impact of child abuse: neuroscience perspective. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(3), 315–316.
    • How exercise influences the brain: a neuroscience perspective. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(2), 169–171.
    • A neuroscience perspective on incidental imaging findings and diagnostic and therapeutic silos. 
      Konopka, L. M.
      Croatian Medical Journal. 2015. 56(1), 68–69.
    • Genetic vulnerability in patients with psychiatric presentations: a neuroscience perspective.
      Konopka, L. M.
      Croatian Medical Journal. 2014. 55(5), 545–546.
    • Neuroscience prospective on education. 
      Konopka, L. M.
      Croatian Medical Journal. 2014. 55(4), 428–430.
    • Marijuana use: neuroscience perspective. 
      Konopka, L. M.
      Croatian Medical Journal. 2014. 55(3), 281–283.
    • Effects of Drawing on Alpha Activity: A Quantitative EEG Study with Implications for Art Therapy.
      Belkofer, C. M., Van Hecke, A. V., & Konopka, L. M.
      Art Therapy. 2014. 31(2), 61–68.
    • Understanding attention deficit disorder: a neuroscience prospective.
      Konopka, L. M.
      Croatian Medical Journal. 2014. 55(2), 174–176.
    • Preliminary Findings of Single- and Multifocused Epileptiform Discharges in Nonepileptic Psychiatric Patients.
      Zimmerman, E. M., & Konopka, L. M.
      Clinical EEG and Neuroscience. 2014. 45(4), 285–292.
    • Where art meets neuroscience: a new horizon of art therapy.
      Konopka, L. M.
      Croatian Medical Journal. 2014. 55(1), 73–74.
    • Neuroscience and psychiatric patients: does the brain matter? Konopka, L. M.
      Croatian Medical Journal. 2013. 54(6), 598–599.
    • Conscious Attention, Meditation, and Bilateral Information Transfer.
      Bob, P., Zimmerman, E. M., Hamilton, E. A., Sheftel, J. G., Bajo, S. D., Raboch, J., … Konopka, L. M.
      Clinical EEG and Neuroscience. 2012. 44(1), 39–43.
    • Multimodality-Driven Diagnostic Interventions: Complex Mild Traumatic Brain Injury.
      Epstein, P., Z. Zimmerman, E., M. Jensen, K., & Konopka, L.
      Journal of Neuropsychiatry. 2012. 24(2):22-22.
    • Use of Multimodality Imaging and Neuropsychological Measures for the Assessment and Treatment of Auditory Verbal Hallucinations: A Brain to Behavior Approach.
      Zimmerman, E. M., Golla, M. A., Paciora, R. A., Epstein, P. S., & Konopka, L. M.
      Activitas Nervosa Superior. 2011. 53(3), 150–158.
    • Person-centered medicine versus personalized medicine: Is it just a sophism? A view from chronic pain management.
      Braš, M., Dorđević, V., Milunović, V., Brajkovic, L., Milicic, D., & Konopka, L.
      Psychiatria Danubina. 2011. 23(3), 245–399.
    • Community-Based Electrophysiological Abnormalities in Children With ADHD: Translating Research Findings into a Clinical Setting.
      Martin, C. N., & Konopka, L. M.
      Activitas Nervosa Superior. 2011. 53(3), 129–140.
    • EEG Complexity and Attentional Processes Related to Dissociative States.
      Bob, P., Golla, M., Epstein, P., & Konopka, L.
      Clinical EEG and Neuroscience. 2011. 42(3), 175–179.
    • Intensity-Dependent Auditory Evoked Potential Defines Subgroups of Patients with PTSD: A Multimodality Imaging Study.
      Poprawski, T. J., Lonser, K. A., Korpics, J., Zadecki, J., Crayton, J. W., Halaris, A., & Konopka, L. M.
      Activitas Nervosa Superior. 2009. 51(3), 109–119.
    • Compulsive Hoarding in an Older Adult with Aggression, Delusions and Memory Loss: A Multimodality Neuroimaging Study.
      Chennamchetty, V. N., Poprawski, T. J., Crayton, J. W., Hamilton, E. A., & Konopka, L. M.
      Activitas Nervosa Superior. 2009. 51(1), 6–11.
    • Conducting Art Therapy Research Using Quantitative EEG Measures.
      Belkofer, C. & Konopka, L. M.
      Art Therapy. 2008. 25(2), 56–63.
    • Multimodality Imaging in a Depressed Patient with Violent Behavior and Temporal Lobe Seizures.
      Poprawski, T. J., Pluzyczka, A. N., Park, Y., Chennamchetty, V. N., Halaris, A., Crayton, J. W., & Konopka, L. M.Clinical EEG and Neuroscience. 2007. 38(3), 175–179.
    • Similar or Disparate Brain Patterns? The Intra-Personal EEG Variability of Three Women with Multiple Personality Disorder.
      Lapointe, A. R., Crayton, J. W., DeVito, R., Fichtner, C. G., & Konopka, L. M.
      Clinical EEG and Neuroscience. 2006. 37(3), 235–242.
    • Frontal Alpha Power Asymmetry in Aggressive Children and Adolescents with Mood and Disruptive Behavior Disorders.
      Rybak, M., Crayton, J. W., Young, I. J., Herba, E., & Konopka, L. M.
      Clinical EEG and Neuroscience. 2006. 37(1), 16–24.
    • EEG Databases in Research and Clinical Practice: Current Status and Future Directions.
      Gordon, A., Konopka, L.M.
      Clinical EEG and Neuroscience. 2005. 36(2), 53–54.
    • Double-blind trial of the effects of tryptophan depletion on depression and cerebral blood flow in smokers.
      Pergadia, M., Spring, B., Konopka, L. M., Twardowska, B., Shirazi, P., & Crayton, J. W.
      Addictive Behaviors. 2004. 29(4), 665–671.
    • Quantitative Electroencephalography in Frontotemporal Dementia with Methylphenidate Response: A Case Study.
      Goforth, H. W., Konopka, L., Primeau, M., Ruth, A., O’Donnell, K., Patel, R., … Rao, M.
      Clinical EEG and Neuroscience. 2004. 35(2), 108–111.
    • Changes in Regional Cerebral Blood Flow After Electroconvulsive Therapy for Depression.
      Milo, T., Kaufman, G., Barnes, E., Konopka, L., Crayton, J., Ringelstein, J., & Shirazi, P.
      The Journal of ECT. 2001. 17(1), 15–21.
    • Individual differences among cocaine users.
      Gunnarsdóttir, E. D., Pingitore, R. A., Spring, B. J., Konopka, L. M., Crayton, J. W., Milo, T., & Shirazi, P.
      Addictive Behaviors. 2000. 25(5), 641–652.
    • Platelet cytosolic calcium hyperresponsivity to serotonin in patients with hypertension and depressive symptoms.
      Delisi, J. S. M., Konopka, L. M., Russell, K., O’Connor, F. L., Cooper, R., & Crayton, J.
      Biological Psychiatry. 1999. 45(8), 1035–1041.
    • Platelet Cytosolic Calcium Responses to Serotonin in Depressed Patients and Controls: Relationship to Symptomatology and Medication.
      Delisi, S. M., Konopka, L. M., O’Connor, F. L., & Crayton, J. W.
      Biological Psychiatry. 1998. 43(5), 327–334.
    • Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients.
      Konopka, L. M., Cooper, R., & Crayton, J. W.
      Biological Psychiatry. 1996. 39(8), 708–713.
    • Spontaneous transients of [Ca2+]i depend on external calcium and the activation of L-type voltage-gated calcium channels in a clonal pituitary cell line (AtT-20) of cultured mouse corticotropes.
      Fiekers, J. F., & Konopka, L. M.
      Cell Calcium. 1996. 19(4), 327–336.
    • “Unusual Tc-99 HMPAO brainpatterns in neurological and neuropsychiatric disorders”.
      Papatheofanis F.J., Shirazi P.H., Konopka L.M., Crayton J.W.
      Radiographic 15:1270, Selected Scientific Exhibits in Neuro-Radiology, Supplement 2, 1995.
    • Serotonin-induced changes in membrane potential and cytosolic free calcium in a clonal pituitary cell line (AtT-20) of cultured mouse corticotropes.
      Fiekers, J. F., & Konopka, L. M.
      Life Sciences. 1994. 55(1), 15–26.
    • Bethanechol-induced responses in mudpuppy parasympathetic neurons.
      Konopka, L. M., & Parsons, R. L.
      Neuropharmacology. 1992. 31(12), 1311–1321.
    • Aminergic and peptidergic elements and actions in a cardiac parasympathetic ganglion.
      Konopka, L. M., Merriam, L., Hardwick, J., & L. Parsons, R.
      Canadian Journal of Physiology and Pharmacology. 1992. 70:s32-s43.
    • Galanin-like innervation of rat submandibular and sublingual salivary glands: Origin and effect on acinar cell membranes.
      Konopka, L. M., May, V., & Forehand, C. J.
      Journal of Comparative Neurology. 1992. 317(3), 271–282.
    • Analysis of the galanin-induced decrease in membrane excitability in mudpuppy parasympathetic neurons. 
      Parsons, R. L., & Konopka, L. M.
      Neuroscience. 1991. 43(2), 647–660.
    • Galanin as an inhibitory transmitter in the mudpuppy cardiac ganglion. 
      McKeon, T. W., Konopka, L. M., & Parsons, R. L.
      Journal of the Autonomic Nervous System. 1991. 33(2), 119–120.
    • Galanin in a parasympathetic ganglion. 
      Konopka, L.M., McKeon, T.W., Merriam, L.A., Hardwick, J.C., Parsons, R.L.
      In: Hokfelt T, Bartfai T., eds. Galanin: A new multifunctional peptide in the neuroendocrine system.
      New York: MacMillan Press. 1991.
    • Galanin-induced hyperpolarization of mudpuppy neurons is calcium dependent.
      Parsons, R. L., & Konopka, L. M.
      Neuroscience Letters. 1990. 115(2), 207–212.
    • Distribution of galanin-like peptide in various tissues of Necturus
      McKeon, T. W., Carraway, R. E., Konopka, L. M., & Parsons, R. L.
      Cell and Tissue Research. 1990. 262(3), 461–466.
    • Frog sympathetic ganglion cells have local axon collaterals. 
      Forehand, C. J., & Konopka, L. M.
      Journal of Comparative Neurology. 1989. 289(2), 294–303.
    • Characteristics of the galanin-induced depolarization of mudpuppy parasympathetic postganglionic neurons. 
      Konopka, L. M., & Parsons, R. L.
      Neuroscience Letters. 1989. 99(1), 142–146.
    • Galanin-induced hyperpolarization and decreased membrane excitability of neurones in mudpuppy cardiac ganglia. 
      Konopka, L. M., McKeon, T. W., & Parsons, R. L.
      The Journal of Physiology. 1989. 410, 107–122.
    • The presence and possible role of a galanin-like peptide in the mudpuppy heart. 
      Parsons, R.L., Neel, D.S., Konopka, L.M., McKeon, T.W.
      Neuroscience. 1989. 29, 749-759.
    • Clindamycin-induced alteration of ganglionic function. II. Effect of nicotinic receptor-channel function. 
      Konopka, L. M., Neel, D. S., & Parsons, R. L.
      Brain Research. 1988. 458(2), 278–284.
    • Clindamycin-induced alteration of ganglionic function. I. Direct effects on ganglion cell properties. 
      Konopka, L. M., & Parsons, R. L.
      Brain Research. 1988. 458(2), 269–277.
    • Localization of Postganglionic Neurons to the Male Genital Organ in the Major Pelvic Ganglion of the Rat. 
      Shimzu, T., Egan-Konopka, L. M., Ohta, Y., & Dun, N. J.
      The Tohoku Journal of Experimental Medicine. 1982. 136(3), 351–352.